WHO WE ARE:

BurnsAdler Pharmaceuticals licenses and acquires rights to pharmaceuticals primarily outside the continental United States.  We promote and sell our pharmaceuticals via our sales representatives and local partners around the world.  For name patient programs and Orphan/niche products we market directly to clinics, physician offices and hospitals in more than 15 countries. [MORE]

NEWS:

March 25, 2010
Colmesdant Receives Marketing Authorization in Mexico

January 8, 2010
Gentalyn Receives Marketing Authorization in Chile

September 23, 2009
BurnsAdler Partners with Three Rivers Pharmaceuticals to Commercialize Infergen in Brazil and Chile

September 10, 2008
BurnsAdler Announces Named Patient Access Program for Latin America in Collaboration with DOR BioPharma

March 24, 2008
Collatamp™ EG Receives Marketing Authorization in Brazil

March 5, 2007              BurnsAdler Partners with X-GEN to Return Colistimethate for Injection to the Mexican Market